Voya Investment Management LLC Inhibrx, Inc. Transaction History

Voya Investment Management LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Dec 06, 2024	BUY	$32.76 - $39.56 $371,694 - $448,847	11,346 New	11,346 $396,000
Q1 2024 May 15, 2024	SELL	$32.76 - $39.56 $90,188 - $108,908	-2,753 Reduced 19.53%	11,346 $396,000
Q4 2023 Feb 14, 2024	BUY	$14.5 - $38.0 $3,393 - $8,892	234 Added 1.69%	14,099 $535,000
Q3 2023 Nov 14, 2023	BUY	$15.75 - $26.31 $3,575 - $5,972	227 Added 1.66%	13,865 $254,000
Q2 2023 Aug 14, 2023	BUY	$16.96 - $27.82 $18,333 - $30,073	1,081 Added 8.61%	13,638 $354,000
Q4 2022 Feb 14, 2023	BUY	$20.18 - $33.33 $15,821 - $26,130	784 Added 6.66%	12,557 $309,000
Q3 2022 Mar 03, 2023	SELL	$11.58 - $24.73 $9,078 - $19,388	-784 Reduced 6.24%	11,773 $211,000
Q3 2022 Nov 14, 2022	BUY	$11.58 - $24.73 $9,761 - $20,847	843 Added 7.71%	11,773 $211,000
Q4 2021 Feb 14, 2022	SELL	$26.75 - $46.02 $5,992 - $10,308	-224 Reduced 2.01%	10,930 $477,000
Q2 2021 Aug 16, 2021	BUY	$14.69 - $27.52 $163,852 - $306,958	11,154 New	11,154 $307,000

18.6K

Ticker INBX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,057,700
Market Cap $570M
Description
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcin...

Get notified when there are updates to the investment portfolio of Voya Investment Management LLC, based on Form 13F filings with the SEC.

Stay updated on Voya Investment Management LLC with notifications on news.